Review of survival analyses published in cancer journals.
Review of survival analyses published in cancer journals.
复制标题
在癌症期刊上发表的生存分析的综述。
DOI：
10.1038/bjc.1995.364
复制
发表时间：
1995-08
影响因子：
8.8
通讯作者：
Stepniewska, K A
中科院分区：
文献类型：
--
作者：
Altman, D G;De Stavola, B L;Love, S B;Stepniewska, K A
在过去的10-15年中，生存分析在医学中得到了广泛的应用。然而，目前还没有发表关于生存分析的使用和介绍的综述。我们对1991年10月至12月在5种临床肿瘤学期刊上发表的研究论文进行了系统的回顾。共审查了132篇论文。我们研究了研究设计、数据处理、分析和结果呈现的几个方面。我们发现，几乎一半的论文没有给出任何随访时间的总结; 62%的论文中至少有一个终点没有明确定义;对数秩和多变量分析经常仅报告为P值[63/84（75%）和22/47（47%）]。此外，尽管许多研究规模较小，但很少表明估计值的不确定性[13/84（15%）的对数秩和16/47（34%）的多变量结果]。仅在8/49（16%）篇论文中解释了对数秩分析中连续变量的分类程序。在43/117（37%）篇至少包括一条生存曲线的论文中，认为图形质量较差。为了解决在这篇综述中发现的一些表述上的不足之处，我们在医学期刊中纳入了生存分析表述的新建议指南。这些将补充一些临床肿瘤学期刊推荐的统计指南。
Survival analysis has found widespread applications in medicine in the last 10-15 years. However, there has been no published review of the use and presentation of survival analyses. We have carried out a systematic review of the research papers published between October and December 1991 in five clinical oncology journals. A total of 132 papers were reviewed. We looked at several aspects of study design, data handling, analysis and presentation of the results. We found that almost half of the papers did not give any summary of length of follow-up; that in 62% of papers at least one end point was not clearly defined; and that both logrank and multivariate analyses were frequently reported at most only as P-values [63/84 (75%) and 22/47 (47%) respectively]. Furthermore, although many studies were small, uncertainty of the estimates was rarely indicated [in 13/84 (15%) logrank and 16/47 (34%) multivariate results]. The procedure for categorisation of continuous variables in logrank analyses was explained in only 8/49 (16%) papers. The quality of graphs was felt to be poor in 43/117 (37%) papers which included at least one survival curve. To address some of the presentational inadequacies found in this review we include new suggested guidelines for the presentation of survival analyses in medical journals. These would complement the statistical guidelines recommended by several clinical oncology journals.